The U.S. Food and Drug Administration has approved a new insulin drug that will allow diabetics to set needles aside at mealtimes and use inhalers instead.
Afrezza Inhalation Powder, however, is not a substitute for long-acting insulin. The new drug is intended to be used in combination with long-acting insulin for patients with type 1 diabetes, the FDA said. However, a clinical trial showed that Afrezza was effective in treating both types of diabetes...
Also read: Iraqi armored division closing in on Mosul